Dr. Sigurd Berven to Highlight NOCISCAN Capabilities, Combining MR Spectroscopy and Augmented Intelligence (AI) NOCISCAN as New Gold Standard in Identifying…
As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast cancer patients may be considered…
CORRECTION - Financial agenda for 2025 Villepinte, 13 janvier 2025: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and…
Heron's Key Phase II Expansion A rendering of Heron’s Key’s Phase II expansion in Gig Harbor, WA, featuring new apartments,…
Net Revenue of $74.4 million, up 0.3% from $74.2 million in the third quarter of 2024Gross Profit Margin of 50.2%,…
NEW YORK, Jan. 31, 2025 /PRNewswire/ -- Report on how AI is driving market transformation - The global alternative credentials…
NEW YORK, Jan. 31, 2025 /PRNewswire/ -- Report with market evolution powered by AI - The global high throughput screening (HTS)…
Vancouver, British Columbia--(Newsfile Corp. - January 31, 2025) - Lyra Growth Partners Inc. ("Lyra") announces that, on January 31, 2025,…
Montreal, Quebec--(Newsfile Corp. - January 31, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the…
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 31, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host…